Frontlight ResearchEarly access
CompletedNo phase
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
Key facts
- Who runs it
- Inflammatix
- Where
- Atlanta, Baltimore, Boston, Charleston, Cleveland, Danville, Detroit, Duluth, El Paso, Houston, Iowa City, Jacksonville, Lexington, Los Angeles, Milwaukee, Mobile, Montclair, Nashville, Oklahoma City, Pittsburgh, Rochester, Sacramento, Springfield, St Louis, and Washington D.C., United StatesSee the 25 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- People taking part
- 1,441 people enrolled
- Started
- 28 Feb 2020
- Ended
- 30 Sept 2024
- Type of study
- Observational
- Treatments tested
- TriVerity
- Record updated
- 22 October 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age >18 year
- Suspected acute infection (respiratory, urinary, abdominal, skin \& soft-tissue), and at least one of the symptoms OR, Suspected sepsis of any cause as defined by a blood culture order by the treating physician, and at least two of the symptoms:; Heart rate: >90 beats/ minute; Temperature: >38 C or <36C; Respiratory Rate: >20 breaths / minutes or PaO2 of <60 mmHg or SpO2 <90%; Systolic blood pressure: <100 mmHg; Altered mental status: Per clinical exam
- Able to provide informed consent, or consent by legally authorized representative
Who cannot take part
- Patient-reported treatment with systemic antibiotics, systemic antiviral agents or systemic antifungal agents within the past 7 days prior to the emergency department study visit. Participants will not be excluded for use of:; Antiviral treatment for HIV infection and hepatitis B and hepatitis C; Topical antibiotics, topical antiviral or topical antifungal agents; Anti-herpes prophylaxis aiding suppression of a recuring herpes infection; Peri-operative (prophylactic) antibiotics; A single dose of antimicrobials during the present ED visit (<10h before blood draw); note single dose can be considered mono or combination therapy, wherein combination is administered as part of local Standard of Care and only one dose of each medication is administered within the allowable 10-hour window
- Patients receiving palliative or hospice care, or those receiving limited interventional care
- Patients receiving experimental therapy or already enrolled in an interventional clinical trial in which a subject receives some type of intervention, which can include but is not limited to investigational drugs, medical devices, or vaccines; Subjects that are enrolled in non-interventional or observational clinical trials will be allowed to participate in this clinical trial
- Patients previously enrolled in the present clinical trial
- Participants will be ineligible for this study if they meet any of the following criteria:
- Prisoners, mentally disabled, or unable to give consent. Should the patient not be able to provide informed consent the legally authorized representative can provide the consent on behalf of the patient
Where in United States
Also in 1 other country, 1 site
- Emory UniversityAtlanta, United States
- Johns Hopkins HospitalBaltimore, United States
- Beth Israel Deaconess Medical CenterBoston, United States
- Medical University of South CarolinaCharleston, United States
- Cleveland ClinicCleveland, United States
- Geisinger HealthDanville, United States
- Henry Ford HospitalDetroit, United States
- Essentia Institute of Rural HealthDuluth, United States
- Texas Tech University Health Sciences Center-El PasoEl Paso, United States
- Baylor College of MedicineHouston, United States
- University of IowaIowa City, United States
- University of Florida (UF) - JacksonvilleJacksonville, United States
- University of KentuckyLexington, United States
- University of Southern CaliforniaLos Angeles, United States
- Medical College of WisconsinMilwaukee, United States
- University of South AlabamaMobile, United States
- Hackensack Meridian HealthMontclair, United States
- Vanderbilt University Medical CenterNashville, United States
- Oklahoma University HealthOklahoma City, United States
- University of PittsburghPittsburgh, United States
- Mayo ClinicRochester, United States
- University of California, Davis Medical CenterSacramento, United States
- Baystate Medical CenterSpringfield, United States
- Washington UniversitySt Louis, United States
- Medstar Health Research InstituteWashington D.C., United States
About the trial
What the trial wants to find out
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin \& soft tissue infections; or suspected sepsis of any cause.
Treatments tested
- TriVerity
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- A standardized protocol using clinical adjudication to define true infection status in patients presenting to the emergency department with suspected infections and/or sepsis.Diagnostic microbiology and infectious disease, 2024
- Record updated
- 22 October 2024